You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 4, 2024

CLINICAL TRIALS PROFILE FOR DIMETHYL FUMARATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Dimethyl Fumarate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00420212 ↗ Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis Completed Biogen Phase 3 2007-01-01 To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. To determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for the disease to get worse. The purpose of this study is also to determine the safety of BG00012 and how well it is tolerated. Another goal is to see what effect BG00012 may have on tests and evaluations used to assess MS.
NCT00451451 ↗ Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis Completed Biogen Phase 3 2007-06-01 To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. Other goals of the study are to determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for MS to get worse. Other objectives of the study are to determine the safety and tolerability of BG00012, as well as the effect it may have on tests and evaluations used to assess MS. Additionally, glatiramer acetate is being used to compare its benefits and risks with placebo and BG00012.
NCT00835770 ↗ BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) Completed Biogen Phase 3 2009-02-03 The primary objective of this study is to evaluate the long-term safety profile of BG00012 (dimethyl fumarate). Secondary objectives of this study are to evaluate the long-term efficacy of BG00012 using clinical endpoints and disability progression, to evaluate further the long-term effects of BG00012 on multiple sclerosis (MS) brain lesions on magnetic resonance imaging (MRI) scans in participants who had MRI scans as part of Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451) and to evaluate the long-term effects of BG00012 on health economics assessments and the visual function test.
NCT01156311 ↗ BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis Completed Biogen Phase 2 2010-06-01 The primary objective of the study is to evaluate the safety and tolerability of BG00012 (dimethyl fumarate) administered in combination with interferon b (IFNß) or glatiramer acetate (GA) in participants with relapsing-remitting multiple sclerosis (RRMS).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dimethyl Fumarate

Condition Name

Condition Name for Dimethyl Fumarate
Intervention Trials
Multiple Sclerosis 22
Relapsing-Remitting Multiple Sclerosis 13
Multiple Sclerosis, Relapsing-Remitting 12
Relapsing Remitting Multiple Sclerosis 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dimethyl Fumarate
Intervention Trials
Multiple Sclerosis 53
Sclerosis 45
Multiple Sclerosis, Relapsing-Remitting 30
Cerebral Infarction 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dimethyl Fumarate

Trials by Country

Trials by Country for Dimethyl Fumarate
Location Trials
United States 385
France 42
Canada 34
Germany 30
United Kingdom 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dimethyl Fumarate
Location Trials
California 18
Texas 17
Florida 17
North Carolina 16
New York 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dimethyl Fumarate

Clinical Trial Phase

Clinical Trial Phase for Dimethyl Fumarate
Clinical Trial Phase Trials
Phase 4 20
Phase 3 17
Phase 2/Phase 3 1
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dimethyl Fumarate
Clinical Trial Phase Trials
Completed 36
Terminated 12
Withdrawn 7
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dimethyl Fumarate

Sponsor Name

Sponsor Name for Dimethyl Fumarate
Sponsor Trials
Biogen 47
Xuanwu Hospital, Beijing 4
EMD Serono 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dimethyl Fumarate
Sponsor Trials
Industry 58
Other 41
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.